Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy
- PMID: 19193487
- DOI: 10.1016/j.eururo.2009.01.040
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy
Abstract
Background: The clinical significance of tumor-infiltrating dendritic cells (TIDCs) and tumor-associated macrophages (TAMs) as markers of immune response has been reported for many cancers.
Objective: To measure tumor infiltration by CD83(+) dendritic cells (DCs) and CD68(+) macrophages in non-muscle-invasive urothelial cancer (NMIUC) prior to bacillus Calmette-Guérin (BCG) immunotherapy and to evaluate their significance in the response to immunotherapy.
Design, setting, and participants: Patients with NMIUC at high risk of recurrence and progression were recruited for a study on markers of the response to BCG.
Intervention: Patients were treated by transurethral resection followed by maintenance BCG.
Measurements: Immunohistochemical staining with anti-CD83 and anti-CD68 monoclonal antibodies on 53 and 46 NMIUC tumors, respectively, prior to BCG treatment. A scoring index was calculated based on the average density of positive cells within the papillary axis, the stroma, lymphoid aggregates, and infiltration into tumors.
Results and limitations: CD83(+) TIDCs were observed mostly within lymphoid aggregates. Multivariate Cox regression analysis showed that maintenance BCG (more than one maintenance cycle) was highly effective in patients with a low level of CD83(+) TIDCs at time of resection (hazard ratio [HR]: 0.035; p=0.002) but showed reduced efficacy in patients with a high level of CD83(+) TIDCs (HR: 0.87; p=0.810). A high level of infiltration by CD83(+) TIDCs slightly decreased the risk of recurrence in patients treated with one or no maintenance BCG cycle (HR: 0.4; p=0.117). In the same population, a strong infiltration of CD68(+) TAMs was associated with an increased risk of recurrence (HR: 3.8; p=0.013).
Conclusions: These results suggest that patients with a high level of infiltration by CD83(+) TIDCs or CD68(+) TAMs do not respond as well to BCG immunotherapy. If confirmed in larger cohorts, the pretreatment level of infiltration by these cells may be useful to influence the choice of treatment strategy.
Comment in
-
Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.Eur Urol. 2009 Jun;55(6):1395-6. doi: 10.1016/j.eururo.2009.01.041. Epub 2009 Feb 3. Eur Urol. 2009. PMID: 19193488 No abstract available.
Similar articles
-
High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.Hum Pathol. 2013 Aug;44(8):1630-7. doi: 10.1016/j.humpath.2013.01.014. Epub 2013 Apr 8. Hum Pathol. 2013. PMID: 23574787
-
Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.Eur Urol. 2009 Jun;55(6):1395-6. doi: 10.1016/j.eururo.2009.01.041. Epub 2009 Feb 3. Eur Urol. 2009. PMID: 19193488 No abstract available.
-
An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.J Urol. 2008 Oct;180(4):1297-300; discussion 1300. doi: 10.1016/j.juro.2008.06.034. Epub 2008 Aug 15. J Urol. 2008. PMID: 18707737
-
The management of superficial bladder cancer.Nat Clin Pract Urol. 2007 May;4(5):254-60. doi: 10.1038/ncpuro0784. Nat Clin Pract Urol. 2007. PMID: 17483810 Review.
-
Intravesical therapy for bladder cancer.Expert Opin Pharmacother. 2010 Apr;11(6):947-58. doi: 10.1517/14656561003657145. Expert Opin Pharmacother. 2010. PMID: 20205607 Review.
Cited by
-
Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder.Cancers (Basel). 2020 Sep 21;12(9):2692. doi: 10.3390/cancers12092692. Cancers (Basel). 2020. PMID: 32967190 Free PMC article. Review.
-
Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.Cancer Immunol Immunother. 2022 Jun;71(6):1507-1517. doi: 10.1007/s00262-021-03063-7. Epub 2021 Oct 31. Cancer Immunol Immunother. 2022. PMID: 34718847 Free PMC article.
-
Immunological basis in the pathogenesis and treatment of bladder cancer.Expert Rev Clin Immunol. 2015 Feb;11(2):265-79. doi: 10.1586/1744666X.2015.983082. Epub 2014 Nov 13. Expert Rev Clin Immunol. 2015. PMID: 25391391 Free PMC article. Review.
-
Review of BCG immunotherapy for bladder cancer.Clin Microbiol Rev. 2025 Mar 13;38(1):e0019423. doi: 10.1128/cmr.00194-23. Epub 2025 Feb 11. Clin Microbiol Rev. 2025. PMID: 39932308 Review.
-
Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis.Oncotarget. 2018 May 18;9(38):25294-25303. doi: 10.18632/oncotarget.25334. eCollection 2018 May 18. Oncotarget. 2018. PMID: 29861872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical